19:28:13 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget är inriktade mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande läkemedelskandidater. Huvudkontoret ligger i Huddinge.

Kalender

2022-02-24 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-31 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-01 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2021-06-10 10:00:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentation and poster on its lead candidate non-opioid drug ACD440 for neuropathic pain, which was presented at the IASP 2021 World Congress on Pain June 9-11 and 16-18 are now available in full on the company’s website.

The poster presentation, given by Matthias Rother, Medical Program Director at AlzeCure, presents the results and conclusions from the Phase Ib clinical study with the TRPV1 antagonist ACD440, which AlzeCure announced positive clinical data from on April 19, 2021. Conclusions show that no topical (erythema, desquamation, pruritus) or systemic adverse events were reported in the study and that ACD440 appears to be safe to be used on normal skin, inflamed skin, and skin with a compromised barrier function. Pharmacodynamic data showed the ACD440 gel had a highly significant analgesic effect both on laser evoked pain and mechanical sensitivity. This effect was seen in all three skin conditions indicating the potential use of the product in multiple skin types.
 
“The results and conclusion presented in the poster presentation are very encouraging and strengthen our belief in the drug candidate as well as the pain platform as a whole. We are now planning for the next step, taking ACD440 into Phase II studies in peripheral neuropathic pain,” said Märta Segerdahl, CMO of AlzeCure Pharma AB.
 
“These results are very interesting and promising. I am very much supporting a clinical trial in neuropathic pain patients,” said Dr. Ralf Baron, Professor in Neurology, at the University of Kiel.
 
“The market for neuropathic pain reached over 10 BUSD in 2020, but still the majority of patients do not receive adequate relief with existing treatment. This shows the high unmet medical need and the huge potential for our project. ACD440 could become a first-in-class drug and meet a substantial demand,” said Martin Jönsson, CEO of AlzeCure Pharma AB.
 
The authors for the late-breaking abstract, titled ACD440 – A potent TRPV1 Antagonist for the topical Treatment of Pain include Dr. Märta Segerdahl, project leader and CMO at AlzeCure, Dr. Klaus Schaffler, who conducted the Proof-of-Mechanism study of ACD440, Dr. Johan Sandin, CSO at AlzeCure, and Matthias Rother, Medical Program Director at AlzeCure.
 
The poster and recorded presentation are available on AlzeCure’s website: https://www.alzecurepharma.se/en/presentations-and-interviews/